Long-term algorithmic price projections and institutional models for Compass Pathways (CMPS) estimate broad potential valuation ranges by 2030, reflecting the long-term commercialization timeline for novel mental health therapeutics. However, exact forecasts vary significantly based on clinical trial success rates and future capital requirements.